Vaxcyte (PCVX) Research & Development (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Research & Development of $312.8 million for Q1 2026, up 111.15% year-over-year from $148.1 million in Q1 2025, and up 29.22% quarter-over-quarter from $242.1 million in Q4 2025.
Vaxcyte (PCVX) Research & Development (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Research & Development for 8 consecutive years, with $312.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 111.15% year-over-year to $312.8 million; the TTM figure through Mar 2026 stood at $959.0 million (up 80.87% YoY), while the FY2025 annual figure was $794.3 million, up 66.65% from the prior year.
- Research & Development grew to $312.8 million in Q1 2026 per PCVX's latest filing, from $242.1 million in the prior quarter.
- Across five years, Research & Development topped out at $312.8 million in Q1 2026 and bottomed at $31.7 million in Q1 2022.
- Historically, Research & Development has averaged $122.7 million across 5 years, with a median of $104.2 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development surged 133.4% — and 2024, when it advanced 20.03%.
- Vaxcyte's Research & Development stood at $51.6 million in 2022, then jumped by 101.74% to $104.2 million in 2023, then increased by 28.29% to $133.6 million in 2024, then jumped by 81.16% to $242.1 million in 2025, then rose by 29.22% to $312.8 million in 2026.
- Business Quant data shows PCVX's Research & Development at $312.8 million in Q1 2026, $242.1 million in Q4 2025, and $209.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 267.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 267.85 Mn |
| Mar 31, 2026 | 312.78 Mn |
| Dec 31, 2025 | 242.06 Mn |
| Sep 30, 2025 | 209.93 Mn |
| Jun 30, 2025 | 194.18 Mn |
| Mar 31, 2025 | 148.13 Mn |
| Dec 31, 2024 | 133.61 Mn |
| Sep 30, 2024 | 116.94 Mn |
| Jun 30, 2024 | 131.51 Mn |
| Mar 31, 2024 | 94.59 Mn |
| Dec 31, 2023 | 104.15 Mn |
| Sep 30, 2023 | 97.42 Mn |
| Jun 30, 2023 | 72.69 Mn |
| Mar 31, 2023 | 58.08 Mn |
| Dec 31, 2022 | 51.63 Mn |
| Sep 30, 2022 | 47.68 Mn |
| Jun 30, 2022 | 38.47 Mn |
| Mar 31, 2022 | 31.68 Mn |
| Dec 31, 2021 | 23.07 Mn |
| Sep 30, 2021 | 20.43 Mn |